Anthony Floreani is a Respiratory physician. OpenAlex indexes 34 publications with 815 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Palmetto Health Pkwy Ste 401
Columbia, SC 29212
Telephone
803-296-7332Registry record last updated 21 Jul 2022.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20232 payments
- AstraZeneca Pharmaceuticals LPProgram year20222 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
73.4%Corticosteroid55.3%Trelegy Ellipta53%Breztri Aerosphere20%Breo Ellipta10%Symbicort6%Arnuity Ellipta6%Fluticasone Propionate4%Budesonide-Formoterol Fumarate2%Part D<11 patientsbeta2-Adrenergic Agonist15.1%Albuterol Sulfate Hfa92%Ventolin Hfa8%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
21.6%Corticosteroid12.6%Prednisone100%Part D≥67 patientsProton pump inhibitor6.7%Omeprazole47%Pantoprazole Sodium40%Esomeprazole Magnesium13%Part D<11 patients+ 1 more class in this area
Cancer & immunology
2.2%Kinase inhibitor2.2%Ofev100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Feedlot dust stimulation of interleukin-6 and -8 requires protein kinase Cε in human bronchial epithelial cells
American Journal of Physiology-Lung Cellular and Molecular Physiology
2007 - Cigarette Smoke Extract Increases C5a Receptor Expression in Human Bronchial Epithelial Cells
Journal of Pharmacology and Experimental Therapeutics
2005 - Staggered Transition to Epoprostenol from Treprostinil in Pulmonary Arterial Hypertension
Annals of Pharmacotherapy
2005 - Expression of C5a receptors (CD 88) on human bronchial epithelial cells (HBEC): C5a-mediated release of IL-8 upon HBEC exposure to cigarette smoke
Kluwer Academic Publishers eBooks
2005
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”